Finch Therapeutics Group (NASDAQ:FNCH) versus NKGen Biotech (NYSE:NKGN) Head to Head Contrast

Risk and Volatility

Finch Therapeutics Group has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares Finch Therapeutics Group and NKGen Biotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75 million	($8.82)	-1.44
NKGen Biotech	N/A	N/A	-$82.94 million	($2.45)	-0.05

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Finch Therapeutics Group and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
NKGen Biotech	N/A	N/A	-479.36%

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.